文献速递临床生化临床免疫质量管理与危急值

阿尔茨海默病生物标志物检测的实践现状与 harmonization 挑战:EFLM 协调委员会调查

Current practices and harmonization challenges in Alzheimer's disease biomarkers: an EFLM Committee: Harmonization Survey.
PubMed 文献 · Clin Chem Lab Med · 2026-03-16

欧洲临床化学与检验医学联合会协调委员会通过在线问卷评估成员国阿尔茨海默病脑脊液与血液生物标志物检测实践。共收集来自超过35个国家的316份回复,发现检测前、中、后各环节存在显著异质性,核心标志物临界值、报告单位及SI单位采用差异大。血液标志物应用渐增但协调统一亟需推进。

要点

  • 脑脊液仍是AD诊断主要基质,血液标志物应用逐渐增加。
  • 检测全流程(样本处理、平台、panel、临界值)异质性显著。
  • 核心标志物临界值、报告单位及SI单位采用差异阻碍结果互认。

核心结论

  • AD生物标志物检测虽临床采用日增,但实践高度异质,亟需国际协调统一。

研究设计与样本

  • EFLM协调委员会发起的在线问卷调查,面向EFLM成员,收集316份来自超过35个国家的回复。

主要发现

  • 脑脊液仍为AD诊断主要基质,血液标志物应用日益增多。
  • 检测前、分析及检测后各阶段均存在显著异质性。
  • 核心标志物临界值、报告单位及SI单位采用差异大,阻碍结果共享解读。

临床怎么用

  • 实验室应关注检测前处理、分析平台及检测后解读的标准化,尤其血液标志物。
  • 推动采用统一报告单位和SI单位以促进结果可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Fluid biomarkers are central to the biological definition and diagnosis of Alzheimer's disease (AD). Despite international recommendations, substantial variability persists in laboratory practices. This survey, promoted by the Committee: Harmonisation (C:H) of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), aimed to assess real-world laboratory practices for AD biomarker testing. METHODS: An online survey was distributed to EFLM members. The questionnaire addressed pre-analytical, analytical, and post-analytical practices for cerebrospinal fluid (CSF) and blood-based AD biomarkers. Descriptive statistics were applied. RESULTS: A total of 316 responses from more than 35 countries were collected. CSF remained the primary matrix for AD diagnostics, although blood-based biomarkers were increasingly implemented. Marked heterogeneity was observed across all phases of testing, including sample handling, assay platforms, biomarker panels, and decisional cut-offs. Cut-off values for core biomarkers varied widely, as well as harmonization of reporting unit and the adoption of SI units preventing a shared approach to interpreting the results. CONCLUSIONS: Despite growing clinical adoption, AD biomarker testing remains highly heterogeneous. Coordinated international harmonization of pre-analytical procedures, analytical methods, and post-analytical interpretation, particularly for blood-based biomarkers, is urgently required to ensure reliable and comparable results.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Agnello L, Dukic L, Akvlediani L, et al. Current practices and harmonization challenges in Alzheimer's disease biomarkers: an EFLM Committee: Harmonization Survey. Clin Chem Lab Med. 2026. PMID: 41842757. doi:10.1515/cclm-2026-0168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。